Novel Design of RNA Aptamers as Cancer Inhibitors and Diagnosis Targeting the Tyrosine Kinase Domain of the NT-3 Growth Factor Receptor Using a Computational Sequence-Based Approach

Ashraf M. Muhammad 1,*†, Ali Zari 2, Nouf H. Alsubhi 3, Maryam H. Al-Zahrani 4, Rana Abdullah Alghamdi 5 and Mai M. Labib 6,*†

1 Applied Biotechnology Program, Faculty of Science, Ain Shams University, Cairo 11566, Egypt
2 Department of Biological Sciences, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia; azari@kau.edu.sa
3 Biological Sciences Department, College of Science & Arts, King Abdulaziz University, Rabigh 21911, Saudi Arabia; nhalsubhi@kau.edu.sa
4 Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia; mhsalzahrani@kau.edu.sa
5 Department of Chemistry, College of Sciences & Arts, King Abdulaziz University, Rabigh 21911, Saudi Arabia; raalghamdi3@kau.edu.sa
6 Department of Bioinformatics and Computer Networks, Agriculture Genetic Engineering Research Institute (AGERI), Cairo 12619, Egypt
* Correspondence: muhammadashraf0100491@sci.asu.edu.eg (A.M.M.); mailabib@ageri.sci.eg (M.M.L.)
† These authors contributed equally to this work.

Abstract: Aptamers, the nucleic acid analogs of antibodies, bind to their target molecules with remarkable specificity and sensitivity, making them promising diagnostic and therapeutic tools. The systematic evolution of ligands by exponential enrichment (SELEX) is time-consuming and expensive. However, regardless of those issues, it is the most used in vitro method for selecting aptamers. Therefore, recent studies have used computational approaches to reduce the time and cost associated with the synthesis and selection of aptamers. In an effort to present the potential of computational techniques in aptamer selection, a simple sequence-based method was used to design a 69-nucleotide long aptamer (mod_09) with a relatively stable structure (with a minimum free energy of $-32.2$ kcal/mol) and investigate its binding properties to the tyrosine kinase domain of the NT-3 growth factor receptor, for the first time, by employing computational modeling and docking tools.

Keywords: RNA modeling; aptamer design; molecular docking; in silico; SELEX

1. Introduction

Aptamers, the single-stranded nucleic acid analogs of antibodies, hold a great promise in molecular diagnostics, therapeutics, and drug targeting, due to their sensitivity and high selectivity toward target molecules [1]. The small molecular weight of aptamers provides complex structures with sufficient surface areas to bind their targets with high specificity. Moreover, their ability to form unique and stable secondary structures allows them to create tertiary structures that recognize and bind their targets, and distinguish between the splice variants and post-translational modifications of the same protein [2].

Antibodies have long been applied in molecular diagnostics and clinical medicine [3,4]. However, antibodies have significant disadvantages in their production, such as their costly synthesis, batch-to-batch variation, cross-reactivity, and the possibility of contamination [1,5]. On the other hand, aptamers are easily synthesized and modified, with a high reproducibility [5,6]. Owing to their smaller size than antibodies, aptamers have high...
Molecules 2022, 27, 4518

biocompatibility, low immunogenicity and toxicity, and better transport and tissue penetration properties. Generally, aptamers are more resistant to degradation than antibodies, and their stability can be further increased by chemically modifying the nucleotides to resist the endogenous nucleases [7]. Because they are chemically synthesized, the chemical modifications can be introduced at any desired position in the nucleotide chain [2]. The sugar modifications at the 2’ position (2’-amino, 2’-fluoro, and 2’-O-methyl) are one of the most common adjustments to improve the nuclease resistance [8]. To decrease the nonspecific binding, and make the synthesis process easier and more efficient, the aptamer length should be reduced as much as possible [7].

The systematic evolution of ligands by exponential enrichment (SELEX) approach is used to select aptamers in vitro, which involves the incubation of the target molecules with a pool of oligonucleotides, followed by a myriad of rounds of selection and enrichment to remove the unbound nucleotides and redeem the final aptamer pool [9–11]. As might be expected, this procedure is costly and time-consuming. Different in silico approaches and computational methods, such as modeling techniques and molecular dynamics (MD) simulations, are essential to reduce the time and cost of the selection and production of aptamers [10].

Bioinformatic tools are comprised of a broad range of methods that facilitate aptamer design and investigate their binding capabilities to the proposed targets. The molecular modeling involves the prediction of the secondary structure of RNA from its nucleotides sequence (primary system); then, building a 3D model (tertiary structure) based on this secondary structure [12]. The predicted 3D model can then be used in docking simulations to investigate different poses of the RNA-protein interaction and select the complexes with the lowest binding energies. Afterward, these in silico predictions can be validated through lab experiments to improve the binding properties of the aptamers and ensure the stability of the predicted structures.

The NT-3 growth factor receptor (or tropomyosin receptor kinase C; TrkC) is an 839-amino acid transmembrane protein that features a 286-residue intracellular tyrosine kinase (TyrKc) domain [13]. Despite recent questions surrounding the TrkC-mediated oncogenesis mechanism, the overexpression of TrkC is known to drive cancer cell survival, migration, and metastasis [14]. Most notably, TrkC is overexpressed in neuroblastoma and glioma, and many other human tumors [14–16]. Given the advantages of aptamers for targeted therapy and the overexpression of TrkC in cancer, TrkC presents an exceptional target for aptamer design.

In this study, a high-affinity aptamer targeting the TyrKc domain of the NT-3 growth factor receptor was designed, for the first time, computationally, using a sequence-based approach. First, the TyrKc domain was docked with known aptamers present on the nucleic acid database (NDB) [17]. Then, the aptamer sequence with the highest affinity was used to generate new similar sequences by introducing random point mutations (substitutions) in the original sequence. Finally, the 3D models of these sequences were predicted and employed to assess their binding properties and validate their ability to inhibit the TyrKc domain through molecular docking simulations.

2. Materials and Methods
2.1. Virtual Screening to Identify Probable RNA Candidates

The aptamers were obtained from the NDB [17] by searching for RNA structures and selecting “RNA only” and “Aptamer” in the “Polymer” and “RNA Type” sections, respectively. The 3D structures were downloaded (Table 1) and prepared for docking by deleting undesired and repeated molecules using PyMOL software v 1.8 [18]. The PDB coordinates of the TrkC tyrosine-kinase domain (6KZC, resolution 2.00 Å, [19]) were taken from the Protein Data Bank and prepared by removing the water molecules, adding the polar hydrogens, and deleting the co-crystallized ligand. The dockings were performed globally, no binding site was specified, using the HDOCK web server to perform protein-
protein and protein-DNA/RNA dockings, using a hybrid method combining template-based modeling and ab initio free docking [20–22].

Table 1. List of used PDB codes.

| ID   | ID   | ID   | ID   | ID   | ID   | ID   | ID   | ID   |
|------|------|------|------|------|------|------|------|------|
| 1ddy | 1nta | 2l1v | 2rn1 | 4fe5 | 5bjo | 6c63 | 6gzk | 6ubu |
| 1et4 | 1ntb | 2lun | 2rqj | 4frg | 5kpy | 6c64 | 6k84 | 6up0 |
| 1fft | 1q8n | 2oom | 2rcc | 4l81 | 5lwj | 6e80 | 6p2h | 6v9d |
| 1nbk | 2au4 | 2pn9 | 3gca | 4lvv | 5ob3 | 6e8s | 6pq7 | 6vwt |
| 1nem | 2jyw | 2qbl | 3q50 | 4qqu | 5uza | 6e8t | 6q57 | 6wjr |
| 1nbk | 2au4 | 2pn9 | 3gca | 4lvv | 5ob3 | 6e8s | 6pq7 | 6vwt |

2.2. Generation of New Aptamer Sequences

The sequence of the NDB aptamer with the highest affinity to the target domain was used to generate multiple sequences of the same length, by introducing random point mutations (substitutions) in the original sequence.

2.3. Molecular Modeling and Docking of the New Aptamers

The RNAfold and RNAComposer web servers were used to obtain the minimum free energy (MFE) tertiary RNA analogs of the generated sequences, to be used as ligands in the subsequent analyses [23–26]. The RNAfold generates the MFE secondary structure for each RNA sequence which is used as input by the RNAComposer to build the 3D model. Once again, the newly obtained structures were docked with the target domain to seek the best-bound aptamer.

2.4. Aptamer Optimization and Final Interaction Profiling

The best-bound aptamer was modified to get a more stable structure, and its interaction with the target domain was visualized in more detail to report the amino acids and nucleotides involved in the interaction, using the Protein-Ligand Interaction Profiler (PLIP) web tool [27].

3. Results

3.1. Virtual Screenings

Stronger interactions take place when more contacts are established between the ligands, aptamers in this case, and the target, to form a highly stable complex. From the obtained results, the 71-mer adenine riboswitch aptamer domain from *Vibrio vulnificus* (PDB: 5uza) had the highest binding affinity to the TyrKc domain (Table 2). Riboswitches are the regulatory segments of mRNA molecules (often <100 nt) that regulate the expression of the proteins, due to the binding of a ligand or a small molecule [28]. They comprise two fundamental domains: an aptamer domain that binds the ligand and an expression domain that controls the gene expression via various mechanisms [29].
Table 2. Docking scores of the top ten binding aptamers to the target domain.

| Aptamer | Docking Score |
|---------|---------------|
| 5uza    | −590.1        |
| 6gzk    | −576.3        |
| 5lwj    | −532.8        |
| 2qbz    | −512.5        |
| 2au4    | −504.1        |
| 1q8n    | −490.1        |
| 1nbk    | −475.2        |
| 4lvv    | −473.9        |
| 2lun    | −465.9        |
| 2lvv    | −463.4        |

3.2. Novel Aptamers Generation

The random mutations were introduced in the 5uza sequence, and ten new sequences were generated (Table 3); then, the secondary and tertiary structures were predicted (Figure 1). Some structures, such as seq 08 and 09, have relatively high MFE indicating that the structure might be unstable.

Table 3. Newly generated sequences. Capital letters are the modified nucleotides.

| Identifier | Sequence | Predicted MFE (kcal/mol) |
|------------|----------|--------------------------|
| 5uza       | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −21.5 |
| seq_01     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −21.1 |
| seq_02     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −21.7 |
| seq_03     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −19.9 |
| seq_04     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −17.8 |
| seq_05     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −18.1 |
| seq_06     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −21.5 |
| seq_07     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −17.2 |
| seq_08     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −15.2 |
| seq_09     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −16.4 |
| seq_10     | gggagauruaucuauacuugauuguuucacacacucuuaacucuuaucucc | −19.2 |
Figure 1. Secondary structures of the newly generated sequences from seq_1 to seq_10 (except seq_09). Nucleotides are colored according to their positional entropy, as shown on the horizontal bar. Red and orange colors indicate lower entropy, while blue colors indicate higher entropy.

3.3. Docking Results

The docking simulations assessed the interaction of the novel aptamers with the target domain. As shown in Table 4, four structures had a higher binding affinity to the domain than the main aptamer, indicating that the minor nucleotide variations could improve the aptamer structure stability and its binding properties, which lab experiments can further assess. Since seq 09, the best-binding structure, has a high free energy of $-16.4$ kcal/mol, the structure must be modified and optimized to obtain a more stable structure.
Table 4. Docking results of the newly generated structures.

| Identifier | Docking Score |
|------------|---------------|
| seq_09     | -673.4        |
| seq_10     | -615.6        |
| seq_06     | -612.1        |
| seq_02     | -611.9        |
| seq_08     | -571          |
| seq_04     | -567.3        |
| seq_01     | -563.7        |
| seq_03     | -559.2        |
| seq_05     | -519.5        |
| seq_07     | -498.6        |

3.4. Optimization and Analysis of the Selected Aptamer

A smaller aptamer would have less interference from the steric effect and a lower synthesis field cost [4]. Consequently, some of the nucleotides of the seq_09 aptamer were modified or removed, yielding a 69-nt 3-hairpin modified structure (mod_09) of -32.2 kcal/mol. In addition, the overall structure has much less entropy than the original one (Figure 2). Notably, the modified structure formed a relatively less stable complex with the target domain (score: -591.9) than the original one (-673.4), but it is an acceptable result since it has a better score than the structure obtained from PDB (-590.1).

Figure 2. Secondary structures of (A) seq_09 aptamer and (B) the modified aptamer.

The interaction between the mod_09 aptamer and the target domain has three binding interfaces (Figure 3). The first binding interface is near the 5′ terminal of the aptamer employing two hydrogen bonds between the base G1 and the residue ARG745 and a salt bridge between G3 and ARG678. The second one has a larger surface area as it involves
bridge between G3 and ARG678. The second one has a larger surface area as it involves more interacting partners. A single hydrogen bond is formed between G53 and TYR669, in addition to the three salt bridges between bases U16, A17, and A18 with residues LYS818 and LYS822. The third binding interface has one salt bridge formed between G31 and LYS797, and two hydrogen bonds formed between the bases G29 and G30 with the residues GLN813 and GLN808, respectively (Figure 4).

![Figure 3](image1.png)

Figure 3. Cartoon view of the interaction showing the binding interfaces (pink) between the aptamer (purple) and the TyrKc domain (blue).

![Figure 4](image2.png)

Figure 4. Cartoon view of the aptamer/protein complex, depicting the interacting nucleotides and amino acids in sticks view. Hydrogen bonds are shown in blue lines and salt bridges in yellow dashes.

4. Discussion

The aptamer selection with SELEX has multiple drawbacks that restrict its effectiveness and make it challenging to produce high-affinity aptamers. The SELEX method requires numerous rounds of selection and enrichment, which makes the process last for months [30]. Computational approaches are promising tools to overcome the time and costs of in vitro aptamer selection. Over the last 15 years, a wide range of computational methods have been utilized in designing aptamers [10,31]. The interest in in silico aptamer design is increasing, owing to the reduced usage of chemical reagents and wet-lab equipment and the relatively affordable costs of computational resources. The early studies on the computational design of aptamers aimed to reduce the initial number of oligonucleotides in the SELEX library pool and speed up the process of identifying the appropriate sequences. In this manner, a comprehensive approach was established to predict the structure of the RNA molecules.
and estimate their binding affinity to a target molecule through computational docking, however, this approach had multiple drawbacks, including the requirement of significant computational resources and the need for a considerably long time to generate the 3D structures for a single sequence [32]. Later, another technique that employed algorithms for motif scanning and screening was proposed by analyzing the RNA secondary structures, using a nucleotide transition probability matrix for pool generation and design [33]. In addition to the requirement for a rare parallel system supercomputer, this method was ineffective in discovering novel motifs and screening with tertiary structures, since the data were two-dimensional. A more time-saving workflow designed the aptamers from their 2D structures and modeled the 3D conformations by Rosetta, depending on the pre-docked mutated conformations and MD optimization, followed by a rigid docking procedure for the prediction of the RNA-protein complexes [34]. More recently, a computational approach, slightly similar to our study, was employed for the in silico design of aptamers, targeting the Streptococcus agalactiae surface protein [35]. The workflow comprised of the structural modification of a previously known RNA sequence, followed by the secondary structure prediction and the generation of 3D structures. The binding affinities were determined from the molecular docking simulations.

The present study aims to overcome the SELEX limitations by using a computational method to design aptamers targeting the TrkC tyrosine kinase domain. This study used a simple approach to select an aptamer binding the TyrKc domain of the NT-3 growth factor receptor. First, the known aptamers from the nucleic acid database were docked against the target domain to understand the possible binding sequences. Since this was an adenine-aptamer, it was quite unusual for it to have a high binding affinity to a protein domain. The adenine binding occurs within the aptamer structure between the bases themselves, while the binding of the proteins is more dependent on the outer interfaces. The best-bound sequence was modified to improve the binding properties, by introducing minor nucleotide variations. Consequently, ten new sequences were generated, four of which formed a more stable complex than that originated with the original structure from NDB. The top sequence (seq._09), unsuitably, had a high MFE value, indicating that the structure could be unstable. The structure was modified manually by replacing some of the bases and removing others to address this problem. As a result, a much more stable structure (mod._09) was obtained, as the MFE value decreased from $-16.4$ to $-32.2$ kcal/mol. Despite its relatively high stability, the mod._09 aptamer formed a lower stable complex with the target domain than its precursor. However, it can be considered an acceptable result since it was better than the original structure obtained from NDB.

Despite being simple, this method may contribute to the process of aptamer design in the future to reduce the number of sequences in the initial SELEX pool, by generating more sequences with similar nucleotides distribution or introducing minor mutations, or through coupling with other more sophisticated approaches.

5. Conclusions

In this study, the TyrKc domain of the NT-3 growth factor receptor was used, for the first time, as a target to demonstrate the potential of the bioinformatics methods and computational approaches as promising tools in the area of aptamer design and selection, by employing a complete set of in silico strategies for the development of aptamers, using a simple sequence-based procedure. As a result, a 69-nt aptamer was optimized to have a relatively stable structure and acceptable binding score to the target domain. Since this computer-based aptamer selection method is cost-effective, simple, and does not require sophisticated devices, it can be applied to obtain more stable aptamers or be implemented in other algorithms for aptamer design.

Author Contributions: Conceptualization, M.M.L.; methodology, A.M.M.; writing—original draft preparation, A.M.M.; writing—review and editing, A.Z.; N.H.A.; M.H.A.-Z. and R.A.A.; visualization, A.M.M.; supervision, M.M.L.; project administration, M.M.L. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author, A.M.M, upon request.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

1. Aljohani, M.M.; Cialla-May, D.; Popp, J.; Chinnappan, R.; Al-Kattan, K.; Zouroob, M. Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases. *Molecules* **2022**, *27*, 383. [CrossRef] [PubMed]

2. Thivyanathan, V.; Gorenstein, D.G. Aptamers and the next generation of diagnostic reagents. *Proteom. Clin. Appl.* **2012**, *6*, 563–573. [CrossRef] [PubMed]

3. Huang, M.; Yang, J.; Wang, T.; Song, J.; Xia, J.; Wu, L.; Wang, W.; Wu, Q.; Zhu, Z.; Song, Y.; et al. Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction. *Angew. Chem. Int. Ed.* **2020**, *59*, 4800–4805. [CrossRef] [PubMed]

4. Song, Y.; Song, J.; Wei, X.; Huang, M.; Sun, M.; Zhu, L.; Lin, B.; Shen, H.; Zhu, Z.; Yang, C. Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein. *Anal. Chem.* **2020**, *92*, 9895–9900. [CrossRef]

5. Bauer, M.; Strom, M.; Hammond, D.S.; Shigdar, S. Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic Applications? *Molecules* **2019**, *24*, 4377. [CrossRef]

6. Cai, S.; Yan, J.; Xiong, H.; Liu, Y.; Peng, D.; Liu, Z. Investigations on the interface of nucleic acid aptamers and binding targets. *Anal. Chem.* **2018**, *143*, 5317–5338. [CrossRef]

7. Adachi, T.; Nakamura, Y. Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application. *Molecules* **2019**, *24*, 4229. [CrossRef]

8. Göringer, H.U.; Adler, A.; Forster, N.; Homann, M. Post-SELEX Chemical Optimization of a Trypanosome-Specific RNA Aptamer. *Comb. Chem. High Throughput Screen.* **2008**, *11*, 16–23. [CrossRef]

9. Bayat, P.; Nosrati, R.; Alibolandl, M.; Rafatpanah, H.; Abnous, K.; Khedri, M.; Ramezani, M. SELEX methods on the road to protein targeting with nucleic acid aptamers. *Biochimie* **2018**, *154*, 132–155. [CrossRef]

10. Buglak, A.A.; Samokhvalov, A.V.; Zherdev, A.V.; Dzantiev, B.B. Methods and Applications of In Silico Aptamer Design and Modeling. *Int. J. Mol. Sci.* **2020**, *21*, 8420. [CrossRef]

11. Catuogno, S.; Esposito, C.L. Aptamer Cell-Based Selection: Overview and Advances. *Biomedicines* **2017**, *5*, 49. [CrossRef]

12. Escamilla-Gutiérrez, A.; Ribas-Aparicio, R.M.; Córdova-Espinoza, M.G.; Castelán-Vega, J.A. In silico strategies for modeling RNA aptamers and predicting binding sites of their molecular targets. *Nucleosides, Nucleotides Nucleic Acids* **2021**, *40*, 798–807. [CrossRef]

13. Stoleru, B.; Popescu, A.M.; Tache, D.E.; Neamtu, O.M.; Emami, G.; Tataranu, L.G.; Buteica, A.S.; Dricu, A.; Purcaru, S.O. Tropomyosin-receptor-kinases signaling in the nervous system. *Makdica* **2013**, *6*, 43.

14. Jin, W. Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer. *Cancers* **2020**, *12*, 147. [CrossRef]

15. Lawton, S.; Krishna, N.; Pisklakovaa, A.; Qu, X.; Fenstermacher, D.A.; Fournier, M.; Vrionis, F.D.; Tran, N.; Chan, J.A.; Kentchappa, R.S.; et al. Neurotrophin Signaling via TrkB and TrkC Receptors Promotes the Growth of Brain Tumor-initiating Cells. *J. Biol. Chem.* **2015**, *290*, 3814–3824. [CrossRef] [PubMed]

16. Cocco, E.; Scaltriti, M.; Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat. Rev. Clin. Oncol.* **2018**, *15*, 731–747. [CrossRef] [PubMed]

17. Narayanan, B.C.; Westbrook, J.; Ghosh, S.; Petrov, A.; Sweeney, B.; Zirbel, C.L.; Leontis, N.B.; Berman, H.M. The Nucleic Acid Database: New features and capabilities. *Nucleic Acids Res.* **2013**, *42*, D114–D122. [CrossRef]

18. PyMOL. The *PyMOL Molecular Graphics System*; Version 1.8; Schrodinger: New York, NY, USA, 2015.

19. Cui, S.; Wang, Y.; Wang, Y.; Tang, X.; Ren, X.; Zhang, L.; Xu, Y.; Zhang, Z.; Zhang, Z.-M.; Lu, X.; et al. Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylthynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors. *Eur. J. Med. Chem.* **2019**, *179*, 470–482. [CrossRef]

20. Yan, Y.; Wen, Z.; Wang, X.; Huang, S.-Y. Addressing recent docking challenges: A hybrid strategy to integrate template-based and free protein-protein docking. *Proteins: Struct. Funct. Bioinform.* **2017**, *85*, 497–512. [CrossRef]

21. Yan, Y.; Zhang, D.; Zhou, P.; Li, B.; Huang, S.-Y. HDOCK: A web server for protein–protein and protein–DNA/RNA docking based on a hybrid strategy. *Nucleic Acids Res.* **2017**, *45*, W365–W373. [CrossRef]

22. Yyan, Y.; Tao, H.; He, J.; Huang, S.-Y. The HDOCK server for integrated protein–protein docking. *Nat. Protoc.* **2020**, *15*, 1829–1852. [CrossRef] [PubMed]
23. Lorenz, R.; Bernhart, S.H.; Honer Zu Siederdissen, C.; Tafer, H.; Flamm, C.; Stadler, P.F.; Hofacker, I.L. ViennaRNA Package 2.0. *Algorithms Mol. Biol.* **2011**, *6*, 26. [CrossRef] [PubMed]

24. Gruber, A.; Lorenz, R.; Bernhart, S.H.F.; Neuböck, R.; Hofacker, I.L. The Vienna RNA WebSuite. *Nucleic Acids Res.* **2008**, *36*, W70–W74. [CrossRef] [PubMed]

25. Biesiada, M.; Purzycka, K.J.; Szachniuk, M.; Blazewicz, J.; Adamiak, R.W. Automated RNA 3D Structure Prediction with RNAComposer. In *RNA Structure Determination: Methods and Protocols*; Turner, D.H., Mathews, D.H., Eds.; Springer: New York, NY, USA, 2016; pp. 199–215.

26. Popenda, M.; Szachniuk, M.; Antczak, M.; Purzycka, K.J.; Lukasiak, P.; Bartol, N.; Blazewicz, J.; Adamiak, R.W. Automated 3D structure composition for large RNAs. *Nucleic Acids Res.* **2012**, *40*, e112. [CrossRef]

27. Adasme, M.F.; Linnemann, K.L.; Bolz, S.N.; Kaiser, F.; Salentin, S.; Haupt, V.J.; Schroeder, M. PLIP 2021: Expanding the scope of the protein–ligand interaction profiler to DNA and RNA. *Nucleic Acids Res.* **2021**, *49*, W530–W534. [CrossRef]

28. Yokobayashi, Y. Aptamer-based and aptazyme-based riboswitches in mammalian cells. *Curr. Opin. Chem. Biol.* **2019**, *52*, 72–78. [CrossRef]

29. Tickner, Z.; Farzan, M. Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors. *Pharmaceuticals* **2021**, *14*, 554. [CrossRef]

30. Lee, G.; Jang, G.H.; Kang, H.Y.; Song, G. Predicting aptamer sequences that interact with target proteins using an aptamer-protein interaction classifier and a Monte Carlo tree search approach. *PLoS ONE* **2021**, *16*, e0253760. [CrossRef]

31. Sabri, M.Z.; Hamid, A.A.A.; Hitam, S.M.S.; Rahim, M.Z.A. In-silico selection of aptamer: A review on the revolutionary approach to understand the aptamer design and interaction through computational chemistry. *Mater. Today Proc.* **2019**, *19*, 1572–1581. [CrossRef]

32. Chushak, Y.; Stone, M.O. In silico selection of RNA aptamers. *Nucleic Acids Res.* **2009**, *37*, e87. [CrossRef]

33. Kim, N.; Izzo, J.A.; Elmetwaly, S.; Gan, H.H.; Schlick, T. Computational generation and screening of RNA motifs in large nucleotide sequence pools. *Nucleic Acids Res.* **2010**, *38*, e139. [CrossRef] [PubMed]

34. Warfield, B.M.; Anderson, P.C. Molecular simulations and Markov state modeling reveal the structural diversity and dynamics of a theophylline-binding RNA aptamer in its unbound state. *PLoS ONE* **2017**, *12*, e0176229. [CrossRef] [PubMed]

35. Soon, S.; Nordin, N.A. In silico predictions and optimization of aptamers against Streptococcus agalactiae surface protein using computational docking. *Mater. Today: Proc.* **2019**, *16*, 2096–2100. [CrossRef]